Autopsy report · NCT00287859

Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

“Withdrawn due to low accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 6 months after it had already started.
• Ran for about 2 years 4 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Masonic Cancer Center, University of Minnesota

Sponsor type

University, hospital or other

Conditions

Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer

Interventions

topotecan hydrochloride

Participants

5

Sites

1

Countries

United States

Trials that died the same way

• Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk
  “Withdrawn due to poor accrual” (97% match in meaning)
• Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
  “Funding withdrawn due to inability to accrue” (76% match in meaning)
• A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)
  “Withdrawn for administrative reasons” (76% match in meaning)
• The Effects of Sapropterin Dihydrochloride Supplementation on in Vivo Redox Status in Patients With Classical PKU
  “Withdrawn due to no funding” (75% match in meaning)
• Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1
  “Withdrawn due to lack of resources” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.